Filing Details
- Accession Number:
- 0001203311-17-000034
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-07-07 19:20:33
- Reporting Period:
- 2017-07-05
- Filing Date:
- 2017-07-07
- Accepted Time:
- 2017-07-07 19:20:33
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1060736 | Seattle Genetics Inc | SGEN | Biological Products, (No Disgnostic Substances) (2836) | 911874389 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1167496 | B Clay Siegall | 21823 30Th Drive Se Bothell WA 98021 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-07-05 | 2,229 | $10.29 | 638,664 | No | 4 | M | Direct | |
Common Stock | Disposition | 2017-07-05 | 2,229 | $52.43 | 636,435 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2017-07-05 | 8,194 | $10.29 | 644,629 | No | 4 | M | Direct | |
Common Stock | Disposition | 2017-07-05 | 8,194 | $51.86 | 636,435 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2017-07-05 | 2,229 | $0.00 | 2,229 | $10.29 |
Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2017-07-05 | 8,194 | $0.00 | 8,194 | $10.29 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
18,607 | 2017-08-28 | No | 4 | M | Direct | |
10,413 | 2017-08-28 | No | 4 | M | Direct |
Footnotes
- Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $52.29 to $52.55. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $51.27 to $52.26. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Shares vested at a rate of 25% on 8/28/08 and monthly thereafter until all the shares were fully vested on 8/28/11.